Zevra Therapeutics’ (ZVRA) Buy Rating Reaffirmed at HC Wainwright

Zevra Therapeutics (NASDAQ:ZVRA)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a report issued on Wednesday,Benzinga reports. They presently have a $20.00 price objective on the stock. HC Wainwright’s target price would suggest a potential upside of 119.06% from the company’s previous close. HC Wainwright also issued estimates for Zevra Therapeutics’ FY2028 earnings at $2.51 EPS.

A number of other research analysts also recently commented on ZVRA. Maxim Group boosted their target price on Zevra Therapeutics from $18.00 to $25.00 and gave the company a “buy” rating in a research note on Tuesday, September 24th. William Blair raised Zevra Therapeutics to a “strong-buy” rating in a research report on Friday, August 30th. Guggenheim initiated coverage on shares of Zevra Therapeutics in a report on Monday, October 7th. They issued a “buy” rating and a $20.00 price target for the company. Canaccord Genuity Group decreased their price objective on Zevra Therapeutics from $25.00 to $23.00 and set a “buy” rating on the stock in a report on Thursday, November 14th. Finally, JMP Securities initiated coverage on shares of Zevra Therapeutics in a research report on Tuesday, September 24th. They issued an “outperform” rating and a $17.00 price target for the company. Seven analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $21.00.

Zevra Therapeutics Stock Performance

ZVRA stock opened at $9.13 on Wednesday. Zevra Therapeutics has a fifty-two week low of $4.20 and a fifty-two week high of $9.30. The company has a quick ratio of 2.88, a current ratio of 2.88 and a debt-to-equity ratio of 0.84. The company has a market capitalization of $487.36 million, a P/E ratio of -4.69 and a beta of 1.93. The company has a 50-day simple moving average of $8.12 and a 200 day simple moving average of $6.59.

Zevra Therapeutics (NASDAQ:ZVRA) last issued its earnings results on Tuesday, November 12th. The company reported ($0.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.25). The business had revenue of $3.70 million for the quarter, compared to the consensus estimate of $5.04 million. Zevra Therapeutics had a negative return on equity of 159.54% and a negative net margin of 342.63%. During the same quarter in the previous year, the business posted ($0.40) earnings per share. Sell-side analysts predict that Zevra Therapeutics will post -1.92 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Zevra Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Virtu Financial LLC bought a new position in shares of Zevra Therapeutics during the third quarter valued at $127,000. Barclays PLC raised its holdings in shares of Zevra Therapeutics by 292.6% in the 3rd quarter. Barclays PLC now owns 57,599 shares of the company’s stock worth $399,000 after acquiring an additional 42,926 shares during the last quarter. Geode Capital Management LLC raised its position in Zevra Therapeutics by 14.2% in the 3rd quarter. Geode Capital Management LLC now owns 1,043,864 shares of the company’s stock valued at $7,246,000 after buying an additional 129,600 shares during the last quarter. XTX Topco Ltd bought a new position in shares of Zevra Therapeutics during the third quarter valued at about $94,000. Finally, State Street Corp lifted its position in shares of Zevra Therapeutics by 7.4% during the 3rd quarter. State Street Corp now owns 772,825 shares of the company’s stock worth $5,363,000 after buying an additional 52,966 shares in the last quarter. 35.03% of the stock is currently owned by institutional investors and hedge funds.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.